全文获取类型
收费全文 | 70622篇 |
免费 | 5093篇 |
国内免费 | 2473篇 |
专业分类
耳鼻咽喉 | 318篇 |
儿科学 | 971篇 |
妇产科学 | 1252篇 |
基础医学 | 11826篇 |
口腔科学 | 960篇 |
临床医学 | 3868篇 |
内科学 | 11154篇 |
皮肤病学 | 1096篇 |
神经病学 | 10327篇 |
特种医学 | 839篇 |
外国民族医学 | 19篇 |
外科学 | 4256篇 |
综合类 | 7557篇 |
现状与发展 | 7篇 |
预防医学 | 1610篇 |
眼科学 | 625篇 |
药学 | 13941篇 |
5篇 | |
中国医学 | 1513篇 |
肿瘤学 | 6044篇 |
出版年
2024年 | 45篇 |
2023年 | 777篇 |
2022年 | 1052篇 |
2021年 | 1947篇 |
2020年 | 1802篇 |
2019年 | 1852篇 |
2018年 | 1948篇 |
2017年 | 1963篇 |
2016年 | 2016篇 |
2015年 | 2338篇 |
2014年 | 3878篇 |
2013年 | 5330篇 |
2012年 | 3831篇 |
2011年 | 4507篇 |
2010年 | 3693篇 |
2009年 | 3801篇 |
2008年 | 4127篇 |
2007年 | 3724篇 |
2006年 | 3249篇 |
2005年 | 2814篇 |
2004年 | 2650篇 |
2003年 | 2446篇 |
2002年 | 1961篇 |
2001年 | 1711篇 |
2000年 | 1556篇 |
1999年 | 1338篇 |
1998年 | 1373篇 |
1997年 | 1318篇 |
1996年 | 1144篇 |
1995年 | 1074篇 |
1994年 | 975篇 |
1993年 | 897篇 |
1992年 | 688篇 |
1991年 | 613篇 |
1990年 | 480篇 |
1989年 | 399篇 |
1988年 | 342篇 |
1987年 | 317篇 |
1986年 | 346篇 |
1985年 | 402篇 |
1984年 | 320篇 |
1983年 | 212篇 |
1982年 | 270篇 |
1981年 | 202篇 |
1980年 | 142篇 |
1979年 | 94篇 |
1978年 | 64篇 |
1977年 | 49篇 |
1976年 | 40篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Ziad Saad Derrek Hibar Maggie Fedgchin Vanina Popova Maura L Furey Jaskaran B Singh Hartmuth Kolb Wayne C Drevets Guang Chen 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(9):549
BackgroundAt ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist effects. Preliminary clinical studies showed conflicting results on whether naltrexone, a MOR antagonist, blocks the antidepressant action of ketamine. We examined drug-induced or endogenous MOR involvement in the antidepressant and dissociative responses to esketamine by assessing the effects of a functional single nucleotide polymorphism rs1799971 (A118G) of OPRM1, which is known to alter MOR agonist-mediated responses.MethodsParticipants with treatment-resistant depression from 2 phase III, double-blind, controlled trials of esketamine (or placebo) nasal spray plus an oral antidepressant were genotyped for rs1799971. Participants received the experimental agents twice weekly for 4 weeks. Antidepressant responses were rated using the change in Montgomery–Åsberg Depression Rating Scale (MADRS) score on days 2 and 28 post-dose initiation, and dissociative side effects were assessed using the Clinician-Administered Dissociative-States Scale at 40 minutes post-dose on days 1 and 25.ResultsIn the esketamine + antidepressant arm, no significant genotype effect of single nucleotide polymorphism rs1799971 (A118G) on MADRS score reductions was detected on either day 2 or 28. By contrast, in the antidepressant + placebo arm, there was a significant genotype effect on MADRS score reductions on day 2 and a nonsignificant trend on day 28 towards an improvement in depression symptoms in G-allele carriers. No significant genotype effects on dissociative responses were detected.ConclusionsVariation in rs1799971 (A118G) did not affect the antidepressant response to esketamine + antidepressant. Antidepressant response to antidepressant + placebo was increased in G-allele carriers, compatible with previous reports that release of endorphins/enkephalins may play a role in mediating placebo effect.Trial Registration and NCT02417064; NCT02418585www.clinicaltrials.gov 相似文献
62.
Rachel Shireen Golpanian 《Expert opinion on pharmacotherapy》2020,21(13):1629-1636
ABSTRACT
Introduction
Pruritus is a debilitating symptom that significantly affects the quality of life of patients who suffer from it. Many current and emerging systemic treatments targeting the neural system have been successful in treating itch of various underlying etiologies. 相似文献63.
64.
目的:探讨维生素D受体基因多态性与特发性癫痫的相关性。方法:通过病例对照研究方法,选取91例特发性癫痫患者作为病例组,另选取同期105例健康者作为对照组,抽取所有研究对象外周静脉血提取DNA,采用PCR直接测序法进行维生素D受体基因BsmI(rs1544410)、FokI(rs2228570)、Cdx2(rs11568820)位点多态性检测。结果:病例组与对照组的BsmI与FokI位点基因型频率和等位基因频率无显著差异(P>0.05);Cdx2位点基因型频率存在显著差异(χ2=6.67,P=0.036),等位基因频率无显著差异,该位点发生A/G变异,分布不处于Hardy-Weinberg遗传平衡。在Cdx2位点基因型与特发性癫痫关联性分析中,病例组中Cdx2位点AG基因型是特发性癫痫发病的危险因素(OR=2.222,95% CI:1.190~4.150,P=0.027)。结论:维生素D受体基因Cdx2位点多态性与特发性癫痫具有关联性。 相似文献
65.
66.
67.
68.
Rosacea is a chronic inflammatory disease in face. Hydroxychloroquine (HCQ), an anti-malaria drug, was reported to have anti-inflammation activities. However, the role of HCQ on rosacea remains unclear. In this study, we revealed the potential molecular mechanism by which HCQ improved rosacea in rosacea-like mice and mast cells (MCs). Moreover, the effects of HCQ treatment for rosacea patients were investigated. In this study, we found HCQ ameliorated the rosacea-like phenotype and MCs infiltration. The elevated pro-inflammatory factors and mast cell protease were significantly inhibited by HCQ treatment in rosacea-like mice. In vitro, HCQ suppresses LL37-induced MCs activation in vitro, including the release of inflammatory factors, chemotaxis, degranulation and calcium influx. Moreover, HCQ attenuated LL37-mediated MCs activation partly via inhibiting KCa3.1-mediated calcium signaling. Thus, these evidences suggest HCQ ameliorated rosacea-like dermatitis may be by regulating immune response of MCs. Finally, the 8-week HCQ treatment exerted satisfactory therapeutic effects on erythema and inflammatory lesions of rosacea patients, indicating that it is a promising drug for rosacea in clinical treatment. 相似文献
69.
BackgroundToll-like receptor (TLR) signals play vital roles during the blood-stage of malaria infections. However, the roles of TLR agonists in the regulation of immune responses and the development of protective immunity to malaria remain poorly understood.MethodBALB/c mice were pre-treated with TLR4, TLR7 and TLR9 agonists, followed by infection with Plasmodium chabaudi. After infection, splenic dendritic cells (DCs), Th1 cells and programmed death-1 (PD-1) expressed on Th1 cells, as well as regulatory T cells (Tregs) were analyzed by flow cytometry. The levels of IFN-γ, TNF-α, TGF-β and IL-10 in splenocytes and IgG1 and IgG2a in serum were measured by ELISA.ResultAdministration of TLR4, TLR7 and TLR9 agonists prior to infection improved disease outcomes. All TLR agonists promoted DC activation, and the proportions of Th1 cells increased. In TLR4, TLR7 and TLR9 agonist treated groups the levels of pro-inflammatory cytokines IFN-γ and TNF-α were elevated, and IgG1 and IgG2a serum levels were also significantly increased. TLR4, TLR7 and TLR9 agonists diminished the activation of Tregs and down-regulated the anti-inflammatory cytokines TGF-β and IL-10. Finally, PD-1 expressed on Th1 cells were decreased in TLR4, TLR7 and TLR9 agonist treated groups compared with control groups.ConclusionTLR4, TLR7 and TLR9 agonists activated DC-mediated innate immune responses and adaptive immune response, which against the blood-stage of Plasmodium and might be applied to malaria protection and treatment. 相似文献
70.
孕烷X受体(Pregnane X receptor,PXR)是核受体家族成员之一,可被多种内源性和外源性物质激活。PXR通过诱导药物代谢酶和转运体,在肝脏、肠道、皮肤和血管内皮中发挥重要的解毒作用。此外,PXR还具有调节糖脂代谢、胆固醇代谢、胆红素和胆汁酸代谢、免疫炎症反应等功能。研究证实,PXR已被公认为多种炎症性疾病的有效药物干预靶点,如炎性结肠炎、坏死性肠炎、肝炎、皮炎、糖尿病等。多种中药或其活性成分可以作为PXR受体激动剂通过核因子B(NF-κB)和尾部相关同源盒转录因子2(Cdx2)通路干扰炎症反应,如虎杖、木蝴蝶、黄芩、黄连、丹参、白芷、人参、香附、五味子、高良姜等。本文综述了近年来PXR调节炎症反应的最新研究成果以及中药激活PXR干预炎症反应的机制,以期为今后的研究提供参考。 相似文献